- Home
- EQR vs EXAS Comparison
EQR vs EXAS Comparison
Compare EQR & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQR | EXAS |
|---|---|---|
| Founded | 1993 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.6B | 19.3B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | EQR | EXAS |
|---|---|---|
| Price | $62.93 | $102.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 19 |
| Target Price | $69.92 | ★ $84.27 |
| AVG Volume (30 Days) | ★ 2.4M | 2.3M |
| Earning Date | 02-05-2026 | 02-17-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | ★ 24.49 | N/A |
| EPS | ★ 3.03 | N/A |
| Revenue | $3,078,827,000.00 | ★ $3,082,033,000.00 |
| Revenue This Year | $5.03 | $19.40 |
| Revenue Next Year | $3.42 | $13.54 |
| P/E Ratio | $20.37 | ★ N/A |
| Revenue Growth | 4.69 | ★ 14.47 |
| 52 Week Low | $58.38 | $38.81 |
| 52 Week High | $75.86 | $102.70 |
Technical Indicators
Market Signals| Indicator | EQR | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 57.19 | 70.87 |
| Support Level | $61.32 | $102.12 |
| Resistance Level | $62.58 | $102.56 |
| Average True Range (ATR) | 1.16 | 0.29 |
| MACD | 0.11 | -0.33 |
| Stochastic Oscillator | 82.72 | 49.29 |
Price Performance
Historical ComparisonAbout EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 318 apartment communities with over 86,000 units and is developing three additional properties with 935 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.